A $123M Flare will get Third Rock oncology biotech into the clinic this year

Kyle LaHucik

Senior Reporter

Flare Therapeutics will start its first human trial this year with an investigational urothelial cancer drug after pulling together a $123 million Series B from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A $123M Flare will get Third Rock oncology biotech into the clinic this year

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

Dutch biotech gets $146M for late-stage trials in three metabolic disorders

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

UnitedHealth Group CEO Andrew Witty steps down

A $123M Flare will get Third Rock on­col­o­gy biotech in­to the clin­ic this year

Senior Reporter

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A $123M Flare will get Third Rock oncology biotech into the clinic this year